Loading...
XHKG
8622
Market cap22mUSD
Jul 18, Last price  
0.36HKD
1D
5.88%
1Q
10.77%
IPO
-15.29%
Name

Huakang Biomedical Holdings Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
6.50
EPS
Div Yield, %
Shrs. gr., 5y
3.82%
Rev. gr., 5y
-0.09%
Revenues
25m
+2.96%
19,456,00025,410,00026,541,00028,677,00025,471,00021,967,00026,127,00025,330,00024,629,00025,359,000
Net income
-4m
L-28.09%
7,934,0008,426,000-1,952,000-459,000-284,000-11,627,000-4,220,000-3,075,000-5,782,000-4,158,000
CFO
0k
P
5,455,00011,255,0002,699,000951,000-3,390,000-3,924,000-2,378,0001,286,000-48,0000

Profile

Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.
IPO date
Dec 13, 2018
Employees
80
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
25,359
2.96%
24,629
-2.77%
25,330
-3.05%
Cost of revenue
30,404
29,580
29,653
Unusual Expense (Income)
NOPBT
(5,045)
(4,951)
(4,323)
NOPBT Margin
Operating Taxes
68
Tax Rate
NOPAT
(5,045)
(4,951)
(4,391)
Net income
(4,158)
-28.09%
(5,782)
88.03%
(3,075)
-27.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
467
2,305
BB yield
-1.05%
-3.08%
Debt
Debt current
4,083
3,959
410
Long-term debt
1,177
3,465
528
Deferred revenue
23
38
Other long-term liabilities
8
38
Net debt
(31,235)
(25,511)
(32,365)
Cash flow
Cash from operating activities
(48)
1,286
CAPEX
(1,502)
(811)
Cash from investing activities
(1,153)
(6,109)
Cash from financing activities
1,023
2,324
FCF
(4,123)
(7,043)
(3,216)
Balance
Cash
36,495
32,935
33,303
Long term investments
Excess cash
35,227
31,704
32,036
Stockholders' equity
54,048
755
4,578
Invested Capital
22,912
55,423
52,491
ROIC
ROCE
EV
Common stock shares outstanding
482,436
415,962
404,639
Price
0.15
40.19%
0.11
-42.16%
0.19
-25.40%
Market cap
72,365
62.59%
44,508
-40.54%
74,858
-24.54%
EV
41,130
18,997
42,493
EBITDA
(5,045)
(1,772)
(1,183)
EV/EBITDA
Interest
53
55
Interest/NOPBT